Saturday 17 October 2026 Export RPID’s income statement to Excel — free account

Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS was flat and free cash flow fell 24.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

0.76 0.09 −10.59%

Follow RPID

Alert me

Market cap: $42.4M
P/E: 0.0×
Fwd P/E: −2.1×
Dividend yield: —
F-score: 3/9
Altman Z: −8.86
Beneish M: −5.06
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.14

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	1	7	3	—	—	—	—	—	—	—

Insider Ownership 44.26%

Capital & Financial Ratios $m

Market Cap 42.39

Revenue 35.18

Net Income (51.20)

Free Cash Flow (40.39)

Net Debt (0.63)

Current Ratio 2.55

Debt/Equity 1.08

P/E ratio 0.00

Fwd P/E (2.14)

P/S ratio 1.04

P/B ratio 2.07

Past 5Y EPS Growth —

This Y EPS Growth 10.24%

Next Y EPS Growth 24.14%

Next Y revenue growth 16.95%

Next 5Y EPS Growth 23.23%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 4.16%

10-year low 10-year high

P/B against its own 10 years 68.98%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	92	51	38	20
Receivables	6	8	3	6
Inventory	20	20	18	19
Other	—	—	—	—
	120	81	61	46

	2023	2024	2025	Q'26
Payables	2	3	4	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	19	18	18	18

Compound Annual Growth %

	10y	5y	3y
Sales	—	15.88%	25.15%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(41.30%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	8	8	—	—	—
’25	7	7	8	11	34
’24	6	7	8	8	28
’23	5	5	6	6	23
’22	4	4	5	4	17
’21	5	6	7	5	23
’20	3	3	5	5	16

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(13)	—	—	—
’25	(9)	(10)	(9)	(3)	(31)
’24	(16)	(10)	(9)	(10)	(44)
’23	(17)	(9)	(10)	(9)	(45)
’22	(17)	(15)	(15)	(12)	(59)
’21	(11)	(12)	(19)	(13)	(55)
’20	(8)	(9)	(9)	(5)	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(12)	—	—	—
’25	(9)	(10)	(9)	(3)	(32)
’24	(16)	(11)	(9)	(10)	(46)
’23	(17)	(9)	(10)	(10)	(47)
’22	(19)	(17)	(17)	(12)	(65)
’21	(12)	(12)	(20)	(15)	(58)
’20	(8)	(9)	(9)	(5)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.31)	(0.27)	—	—	—
’25	(0.26)	(0.27)	(0.26)	(0.28)	(1.05)
’24	(0.31)	(0.29)	(0.26)	(0.22)	(1.08)
’23	(0.32)	(0.33)	(0.31)	(0.26)	(1.22)
’22	(0.35)	(0.31)	(0.38)	(0.39)	(1.43)
’21	(34.48)	(20.01)	(0.71)	(0.35)	(3.94)
’20	(22.65)	(26.22)	(23.78)	(30.63)	(103.28)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	9.04	1.12	0.74	0.58	0.91	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	27.04	11.34	1.55	1.34	4.50
People
People	Employees	—	—	—	—	160	202	177	193	163	171
	Revenue/emp, $m	—	—	—	0.00	0.10	0.12	0.10	0.12	0.17	0.20
Income, $m
Income, $m	Revenue	—	—	—	17	16	23	17	23	28	34
	Gross margin, %	—	—	—	(1.42)	(50.20)	(33.32)	(49.85)	(24.36)	(0.39)	3.12
	EBT	—	—	—	(21)	(37)	(73)	(61)	(52)	(47)	(47)
	EBT margin, %	—	—	—	(125.63)	(229.79)	(316.09)	(358.27)	(232.85)	(167.08)	(140.18)
	Net income	—	0	—	(21)	(37)	(74)	(61)	(52)	(47)	(47)
	Depreciation	—	—	—	1	2	2	3	3	3	3
Per share, $
Per share, $	Revenue	—	—	—	47.72	44.78	1.17	0.40	0.52	0.64	0.75
	Earnings	—	—	—	(61.19)	(103.28)	(3.94)	(1.43)	(1.22)	(1.08)	(1.05)
	Cash flow	—	—	—	(61.12)	(86.34)	(2.78)	(1.38)	(1.05)	(1.01)	(0.70)
	Capex	—	—	—	(4.90)	(1.92)	(0.16)	(0.16)	(0.04)	(0.03)	(0.02)
	Free cash flow	—	—	—	(66.02)	(88.26)	(2.94)	(1.54)	(1.09)	(1.04)	(0.71)
	Book value	—	—	—	(238.66)	(353.78)	11.17	3.87	2.74	1.73	0.74
	Shares, m	—	—	—	0	0	20	42	43	44	45
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.69	0.69	9.06	3.02	1.74	1.40	3.86
	P/B	—	—	—	0.00	0.00	0.95	0.32	0.33	0.52	3.90
	EV/Sales	—	—	—	(2.79)	(2.79)	0.75	(2.90)	(2.06)	(0.18)	3.28
	EV/FCF	—	—	—	1.59	1.59	(0.30)	0.76	0.99	0.11	(3.45)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(21)	(31)	(55)	(59)	(45)	(44)	(31)
	Capex	—	—	—	(2)	(1)	(3)	(7)	(2)	(1)	(1)
	Free cash flow	—	—	—	(23)	(32)	(58)	(65)	(47)	(46)	(32)
Balance, $m
Balance, $m	Working capital	—	—	—	13	47	200	120	101	63	43
	Total debt	—	—	—	18	25	0	7	—	—	19
	Net debt	—	—	—	5	(20)	(193)	(101)	(92)	(51)	(19)
	Shareholders’ equity	—	—	—	(83)	(127)	221	164	118	75	33
Returns, %
Returns, %	ROA	—	—	—	(168.01)	(88.94)	(50.15)	(28.16)	(31.41)	(38.81)	(54.47)
	ROIC	—	—	—	0.00	0.00	(105.87)	(62.99)	(136.30)	(126.72)	(214.45)
	ROE	—	—	—	25.40	43.15	(166.07)	(31.58)	(37.19)	(48.50)	(86.82)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MDAI Spectral AI, Inc.	$49.6M	— (loss-making)	— (loss-making)	−30.42% (below 0%: shrinking)	n/m	−21.86% (below 0%: shrinking)	31.58%	(122.70%)	Compare
TLIS Talis Biomedical Corporation	$46.3M	— (loss-making)	— (loss-making)	−94.01% (below 0%: shrinking)	n/m	+23.80% (above 0%: growing)	91.78%	0.00%	Compare
SRTS Sensus Healthcare, Inc.	$45.6M	— (loss-making)	— (loss-making)	−68.69% (below 0%: shrinking)	n/m	−201.65% (below 0%: shrinking)	33.58%	(138.86%)	Compare
TELA TELA Bio, Inc.	$45.6M	— (loss-making)	— (loss-making)	−4.49% (below 0%: shrinking)	n/m	−17.72% (below 0%: shrinking)	72.77%	(48.12%)	Compare
SNWV Sanuwave Health Inc.	$44.5M	3.0×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.5M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)	Compare
RPID Rapid Micro Biosystems, Inc.	$42.4M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)
NNOX Nano-X Imaging Ltd.	$38.6M	— (loss-making)	— (loss-making)	+36.71% (above 0%: growing)	n/m	−21.37% (below 0%: shrinking)	(1,050.87%)	(1,334.91%)	Compare
CVRX CVRx, Inc.	$37.0M	— (loss-making)	— (loss-making)	+15.57% (above 0%: growing)	n/m	−11.18% (below 0%: shrinking)	87.39%	(82.92%)	Compare
Median of peers	$45.0M	—	—	−17.45%	—	−19.54%	65.33%	(65.52%)

All 149 Medical Devices stocks →

Rapid Micro Biosystems, Inc. (RPID) key facts

Strength: Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024.
Rapid Micro Biosystems, Inc. (RPID) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RPID traded at $0.76, a market capitalization of $42.4 million.
Return on equity was −86.8% and debt-to-equity 1.08.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −8.86 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.